

## Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Shubhasree Banerjee<sup>1</sup> · Ann Biehl<sup>2</sup> · Massimo Gadina<sup>3</sup> · Sarfaraz Hasni<sup>4</sup> · Daniella M. Schwartz<sup>5</sup>

Published online: 12 June 2017  
© Springer International Publishing Switzerland 2017

**Erratum to: Drugs (2017) 77:521–546**  
**DOI 10.1007/s40265-017-0701-9**

Page 539, Table 6 Janus Kinase Inhibitors in preclinical and early clinical development

The first row/entry which currently reads:

Drug	Specificity	Clinical Status	Diseases
OP0155 [199]	JAK3	Preclinical	Rat adjuvant induced arthritis

Should read:

Drug	Specificity	Clinical Status	Diseases
PF-06651600 [199]	JAK3	Phase 2 (ClinicalTrials.gov. NCT02969044, NCT02974868, NCT02958865)	Rheumatoid arthritis, alopecia areata, ulcerative colitis

The online version of the original article can be found under doi:[10.1007/s40265-017-0701-9](https://doi.org/10.1007/s40265-017-0701-9).

✉ Shubhasree Banerjee  
shubhasree.banerjee@nih.gov

<sup>1</sup> Rheumatology Fellowship and Training Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA

<sup>2</sup> Clinical Center, National Institutes of Health, Bethesda, USA

<sup>3</sup> Translational Immunology Section, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA

<sup>4</sup> Lupus Clinical Research Program, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA

<sup>5</sup> Molecular Immunology and Inflammation Branch, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA